Patricia Galván - Concepedia

Author

Patricia Galván

Also Known As

A. Llombart-Cussac, Ane Moreno-Oya, Brasó-Maristany, F, Galván, Patricia, Johnston, Stephen, Llombart-Cussac, Antonio, Malumbres, Marcos, Miglietta, F, P Galvan, P Galván

311

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínic de Barcelona Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Vall d'Hebron Institute of Oncology Universitat de Barcelona Vall d'Hebron Hospital Universitari

About

Patricia Galván is an author at Hospital Clínic de Barcelona specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	905
2	Cell Biology	4	4	192
3	Health Sciences	3	3	93
4	Engineering	1	1	60
5	Biomedical Engineering	1	1	22

Patricia Galván

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma Aleix Prat, Alejandro Navarro, Laia Paré, Cancer Research	2017	468
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer Ana Bosch, Zhiqiang Li, Anna Bergamaschi, Science Translational Medicine	2015	418
Frequency and spectrum of PIK3CA somatic mutations in breast cancer Olga Martínez‐Sáez, Núria Chic, Tomás Pascual, Breast Cancer Research	2020	357
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial Antonio Llombart‐Cussac, Javier Cortés, Laia Paré, The Lancet Oncology Breast OncologyMedicinePathologyPathological Complete ResponseImmune Checkpoint Inhibitor	2017	329
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer Juan Miguel Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, Cancer Research	2017	239
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial Aleix Prat, Cristina Saura, Tomás Pascual, The Lancet Oncology Breast OncologyMedicinePharmacologyGynecologyBreast Cancer	2019	191
The Hippo Transducer TAZ Interacts with the SWI/SNF Complex to Regulate Breast Epithelial Lineage Commitment Adam Skibinski, Jerrica L. Breindel, Aleix Prat, Cell Reports	2014	163
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade Aleix Prat, Tomás Pascual, Carmine De Angelis, JNCI Journal of the National Cancer Institute	2019	163
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer Aleix Prat, Valentina Guarneri, Tomás Pascual, EBioMedicine	2022	133
Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib Aleix Prat, Maggie C.U. Cheang, Patricia Galván, JAMA Oncology	2016	122

Page 1